IL6 and COVID-19: While animal models with humanized IL-6 and IL-6R that recapitulate human disease of COVID-19 are under development, future therapeutic experiments in these animal models are absolutely necessary to determine the clinical benefit of pIL6RmAb in reducing IL-6 signaling for cytokine release syndrome-driven diseases, particularly in the context of SARS-CoV-2 infection.